This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire-Movetis NV
Shire-Movetis NV, a prominent biopharmaceutical company headquartered in Belgium, focuses on developing innovative treatments for gastrointestinal disorders. Founded in 2008, the company has made significant strides in the industry, particularly with its flagship product, the novel therapy for irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Shire-Movetis is recognised for its commitment to research and development, ensuring that its offerings address unmet medical needs. The company’s unique approach combines scientific expertise with patient-centric solutions, positioning it as a leader in the gastrointestinal sector. Notable achievements include successful partnerships and a growing portfolio of specialised therapies, solidifying its reputation in the biopharmaceutical landscape.
DitchCarbon Score
How does Shire-Movetis NV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire-Movetis NV's score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire-Movetis NV, headquartered in Belgium (BE), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Takeda Pharmaceutical Company Limited, from which it inherits climate commitments and initiatives. As a current subsidiary of Takeda, Shire-Movetis NV aligns with the sustainability goals set by its parent company. Takeda has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These targets are cascaded down to Shire-Movetis NV, reflecting a commitment to addressing climate change and reducing environmental impact. While specific reduction targets for Shire-Movetis NV are not detailed, the overarching initiatives from Takeda include participation in the Carbon Disclosure Project (CDP) and the RE100 initiative, which focuses on transitioning to 100% renewable energy. Additionally, Takeda is involved in the Race to Zero campaign, further demonstrating its commitment to climate action. In summary, while Shire-Movetis NV does not provide specific emissions data, it is committed to climate initiatives through its relationship with Takeda Pharmaceutical Company Limited, which sets ambitious targets for reducing carbon emissions and promoting sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire-Movetis NV is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
